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Abstract Heart failure has a high prevalence in the gen-
eral population. Morbidity and mortality of heart failure pa-
tients remain high, despite improvements in drug therapy,
implantable cardioverter-defibrillators and cardiac resyn-
chronisation therapy. New transcatheter implantable devices
have been developed to improve the treatment of heart fail-
ure. There has been a rapid development of minimally inva-
sive or transcatheter devices used in the treatment of heart
failure associated with aortic and mitral valve disease and
these devices are being incorporated into routine clinical
practice at a fast rate. Several other new transcatheter struc-
tural heart interventions for chronic heart failure aimed
at a variety of pathophysiologic approaches are currently
being developed. In this review, we focus on devices used
in the treatment of chronic heart failure by means of left
ventricular remodelling, left atrial pressure reduction, tri-
cuspid regurgitation reduction and neuromodulation. The
clinical evaluations of these devices are early-stage evalua-
tions of initial feasibility and safety studies and additional
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clinical evidence needs to be gathered in appropriately de-
signed clinical trials.
Keywords Heart failure · Transcatheter · Minimally
invasive · Ventricular aneurysm · Tricuspid regurgitation ·
Neuromodulation
Heart failure (HF) is a major public health issue in both de-
veloped and developing countries [1]. In the past 2 decades,
developments in drug therapy, implantable cardioverter-de-
fibrillators and cardiac resynchronisation therapy, as well as
mechanical circulatory support with left ventricular assist
devices and heart transplantation have improved the prog-
nosis of patients with HF and a reduced ejection fraction
(HFrEF) [1]. However, morbidity and mortality rates remain
high [2]. Furthermore, there is no effective pharmacological
treatment for HF patients with a preserved ejection fraction
(HFpEF) [3].
In an attempt to further improve the prognosis and qual-
ity of life of HF patients, several transcatheter implantable
devices have emerged. In this review, we aim to describe
a spectrum of recently introduced devices for the treatment
of chronic HF by means of left ventricular (LV) remod-
elling, reduction of left atrial (LA) pressure, reduction of
tricuspid regurgitation and neuromodulation. To provide an
overview of these devices, this review focusses on describ-
ing these devices, their main procedural characteristics, pa-
tient eligibility, procedural results and clinical outcomes.
Transcatheter devices for aortic valve implantation, mitral
valve replacement/repair, paravalvular leak closure, percu-
taneously delivered biological therapies and interventions
for acute HF fall beyond the scope of this review.
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Fig. 1 Left ventricular remodelling. a Transversal plane of magnetic
resonance imaging showing left ventricular aneurysm caused by apical
myocardial infarction, as visualised by late enhancement. b,c Revivent
TC Ventricular Enhancement System (BioVentrix; San Ramon, CA,
USA). Internal and external anchors of the device work together to
exclude scarred tissue of the left ventricle (b). A computed tomography
scan reconstruction of the heart (anterior view) after the implantation
of a series of anchor pairs (c). (Images adapted with permission from
BioVentrix; San Ramon, CA, USA)
Left ventricular remodelling
Ischaemic heart disease is one of the main causes of HFrEF
[4]. Scar formation after myocardial infarction results in
progressive LV remodelling (Fig. 1a; [4]). Expansion and
thinning of the left ventricle increases its radius and wall
tension, leading to a loss of the typical LV cone shape
[5], thereby inducing inefficient ventricular contraction and
subsequent HF onset.
In classical surgical ventricular reconstruction proce-
dures, the LV aneurysm is resected to reduce volume and
obtain an elliptical shape. Results in multicentre registries
for patients with ischaemic cardiomyopathy have been
promising [6–11]. However, the only randomised trial
thus far (STICH: Surgical Treatment for Ischemic Heart
Failure) failed to demonstrate any benefit in the com-
posite endpoint of death and rehospitalisation for cardiac
causes [12]. Moreover, these procedures have a high sur-
gical risk related to cannulation, cardiopulmonary bypass
and ventriculotomy. That is why they have been largely
abandoned in routine clinical practice. New, less invasive,
transcatheter approaches for ventricular reconstruction have
recently emerged (Tab. 1).
Revivent
The Revivent TC Ventricular Enhancement System (BioVen-
trix; San Ramon, CA, USA) allows major LV reconstruction
on a beating heart without cardiac incisions. The device
is composed of titanium anchor pairs covered in polyester
cloth (Fig. 1b) and connected by an adjustable-length tether
made of high-strength biocompatible poly-ether-ether ke-
tone.
First, the scarred LV segments are exposed. A dedicated
curved needle is inserted in the LV free wall to reach the
septum and right ventricle where its tip can be ‘captured’
through a jugular venous access catheter. This creates a con-
nection wire between the LV access site and the jugular
access site. Over this wire, a fastening anchor is intro-
duced through the catheter and subsequently retracted until
it comes into contact with the right ventricular side of the
intraventricular septum. Next, the catheter is removed and
another fixing anchor is placed on the outer face of the
ventricular wall via the site of needle insertion. Several an-
chors are implanted until optimal plication of the aneurysm
is achieved (Fig. 1c).
Initial, published, data showed good durability and sat-
isfactory results of the Revivent device in 11 patients [13].
Recently, data were presented on the implantation in 71 pa-
tients treated with either the original delivery system that re-
quired a sternotomy (Revivent; 51 patients) or the Revivent
TC System (20 patients). These data showed a reduction of
LV volume, increase of LV ejection fraction and increase in
6-minute walk distance [14]. To confirm results and gather
data on long-term 5-year safety, BRAVE-TC (BioVentrix
Registry Assessment of Ventricular Enhancement for the
Revivent TC) is currently recruiting up to 100 subjects.
Parachute
The Parachute device (CardioKinetix; Menlo Park, CA,
USA) is comprised of a self-expanding frame, a polyte-
trafluoroethylene impermeable membrane and an atrau-
matic foot. The nitinol frame has a conical shape with
16 struts that ends in a 2 mm anchor to engage the my-
ocardium for device stabilisation. The distal foot is radio-
opaque and provides a contact point between the LV apex
and the device in addition to facilitating visualisation for
placement. The device is available in 4 sizes, all in two
heights.
Upon implantation, the left ventricle is accessed via the
transfemoral approach using a conventional pig-tail wire.
A stiff wire is then positioned for support and finally a pre-
shaped catheter is placed near the LV apex. The device is
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Table 1 Transcatheter options for left ventricular reconstruction
Device Status Indication Method Access Off-pump
Revivent (TC) CE mark
December 2012
Revivent;
CE mark
June 2016
Revivent TC
Anteroseptal, anterior or api-
cal scarring incl. pseudochor-
dae and LVDD >70 mm [13]
Reshaping LV by means
of plication wires and
titanium anchors
Medio-sternotomy
Revivent;
Mini-thoracotomy
and jugular Revivent
TC
Yes
Parachute CE mark
October 2012
Anteroseptal, anterior or
apical scarring
Expansion of ePTFE mem-
brane on a nitinol frame
configured as an umbrella
to exclude the aneurysm
Percutaneous Yes
CE Conformité Européene, ePTFE expanded polytetrafluoroethylene, LV left ventricle, LVDD left ventricular diastolic diameter
Table 2 Transcatheter options for transcatheter tricuspid valve repair
Device Status Method Size Access Repositionable
4TECH
TriCinch
System
First-in-man
CE mark multicentre trial [23]
Annulus corkscrew
connected through
a band to a stent in the
IVC
27, 32, 37
and 43 mm
(stent)
21.3 F Yes
Forma Repair
System
First-in-man [24] Foam-filled polymer
balloon spacer fixated
in the RV apex
12 and
15 mm
24 F Yes
Trialign Compassionate use [25];
Completed FDA early feasibility study
(SCOUT)
Multicentre CE mark Trial (SCOUT-II)
Pairs of pledgets to
plicate the posterior
annulus and bicuspidize
the valve
10, 14, 17,
21 mm
(bident
span)
14 F –
Mitraclip Compassionate use [26–28] Edge-to-edge repair 24 F Yes
Millipede
annular ring
First-in-man Adjustable direct
annuloplasty ring
NA NA Yes
Cardioband
Tricuspid
Preclinical
(CE mark mitral cardioband)
Supra-annular fixation
sleeve with anchors
6 sizes
(A–F)
25 F Yes
CE Conformité Européene, IVC inferior vena cava, NA not available, RV right ventricle, NA not applicable
advanced through the sheath until the foot is exposed and
is advanced further until the foot contacts the apex. The
device is deployed by pulling back on the guide catheter
while the delivery catheter is held motionless, i. e. the de-
vice is ‘unsheathed’ by pulling back the outer sheath. The
self-expansion is facilitated by inflating a low-pressure bal-
loon until the anchors are fully expanded and in contact
with the LV wall. Contrast angiography of the left ventri-
cle is performed to confirm positioning before releasing the
device.
The first-in-human study (PARACHUTE IV: PercutA-
neous Ventricular RestorAtion in Chronic Heart FailUre due
to Ischemic HearT DiseasE), demonstrated feasibility and
safety of the device in 34 patients [15]. Procedural success
was 91% with a significant reduction of diastolic volume.
Moreover, 85% of patients improved in their functional
class. Currently, the pivotal randomised PARACHUTE V
trial (NCT01614652) is recruiting to test the parachute de-
vice versus optimal medical therapy in 560 patients. The
study is almost at its halfway enrolment point. Further-
more, the non-randomised observational PARACHUTE V
trial (NCT02543632) is recruiting to assess quality of life
and cardiac output benefit at six months in 105 patients
(25 controls).
Percutaneous tricuspid valve repair
The main causes of tricuspid regurgitation (TR) are annular
dilation and right ventricular enlargement, often secondary
to left-sided heart disease [16]. Moderate to severe TR sig-
nificantly impacts functional status and is an independent
risk factor for poor long-term survival [17–20]. In high-risk
patients with an advanced state of disease, tricuspid surgery
carries an operative mortality of up to 22% and is therefore
frequently averted [21].
The anatomy of the tricuspid valve apparatus is complex.
The aim of minimally invasive approaches for the treatment
of severe, symptomatic TR is placement of transcatheter
valves, either in the position of the native tricuspid valve
or in the caval veins. Here, we will discuss the devices for
direct transcatheter tricuspid repair (Tab. 2).
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Fig. 2 Tricuspid valve repair.
Several devices are being tested
for tricuspid valve repair, for
example the TriCinch System
(4Tech Cardio Ltd., Galway,
Ireland). a Implantation steps of
the TriCinch System. A stainless
steel corkscrew is fixated into
the anteroposterior tricuspid an-
nulus (i) to assure the stability of
the implant. By pulling the sys-
tem through a Dacron band (ii),
the anchoring corkscrew re-
models the anteroposterior
annulus (iii). The tension is
maintained by fixation of a self-
-expanding nitinol stent in the
inferior vena cava (iv). b Com-
puted tomographic sagittal im-
ages of the TriCinch System pre
(left side) and post implantation
(right side). (IVC inferior vena
cava, RA right atrium, RV right
ventricle, SVC superior vena
cava, TV tricuspid valve. Images
adapted with permission from
4Tech Cardio Ltd., Galway,
Ireland)
TriCinch system
The TriCinch System (4Tech Cardio Ltd., Galway, Ire-
land) is a percutaneous device designed for tricuspid valve
remodelling. Transfemoral fixation of a stainless steel
corkscrew into the anteroposterior tricuspid annulus is per-
formed to assure stability. By pulling the system towards
the inferior vena cava through a Dacron band the anchoring
corkscrew remodels the annulus and tension is maintained
by fixation of a self-expanding nitinol stent in the inferior
vena cava (Fig. 2). The stent is available in multiple sizes,
allowing a total indicated vessel diameter ranging from 18
to 35 mm.
The first-in-man case demonstrated the feasibility of the
TriCinch device and showed a reduction in annular dimen-
sions and TR severity [22]. The TriCinch is to be eval-
uated in the PREVENT trial (Percutaneous Treatment of
Tricuspid Valve Regurgitation With the TriCinch System;
NCT02098200): an observational study that aims to include
24 patients to assess the safety and performance of the de-
vice in the treatment of functional TR. The St. Antonius
Hospital participates in this study.
Edwards FORMA repair system
The Forma Repair System (Edwards Lifesciences, Irvine,
CA, USA) is a transcatheter system designed to reduce
TR by occupying the regurgitant orifice area with a foam-
filled polymer balloon, providing a surface for native leaflet
coaptation (Fig. 3). In a first-in-man study, device implan-
tation was successful without procedural complications in
seven patients [23]. An Early Feasibility Study is on-go-
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Fig. 3 FORMA Repair System. The Forma Repair System (Edwards
Lifesciences, Irvine, CA, USA) positioned at the level of the tricuspid
valve annulus, with anchoring system at the right ventricular apex and
excess device length coiled into a subcutaneous pocket. (Image adapted
with permission from Edwards Lifesciences, Irvine, CA, USA)
ing (NCT02471807) and a multicentre study is underway
(NCT02787408).
Millipede IRIS
The Millipede IRIS (Millipede Inc., Santa Rosa, CA, USA)
is an adjustable, semi-rigid, complete annuloplasty ring that
has been used clinically in the mitral and tricuspid position.
The implant consists of a frame, anchors and a cinching
mechanism. With the eight points of the cinching mecha-
nism surrounding the implant the diameter of the frame can
be customised to achieve proper valve leaflet coaptation.
Nine surgical patients have been treated with the IRIS
ring, initially with a temporary placement series. A series
of permanent implants reduced the valve diameter by up to
50% and the MR grade to zero in all but one patient. Re-
cently, the data of the longest follow-up of approximately
six months with echocardiography and computed tomogra-
phy were presented [24]. The data demonstrated the fea-
sibility and efficacy of the annuloplasty ring in surgical
patients. The company is currently completing the delivery
catheter which can deliver the IRIS ring via transfemoral-
transseptal implantation. This device has been used in nu-
merous animal studies.
Cardioband
The Cardioband (Valtech Cardio, Or Yehuda, Israel) is the
first transcatheter direct annuloplasty system designed for
mitral and tricuspid repair. The Cardioband received its
CE Mark for mitral valve repair in September 2015 [25].
A modified system for the treatment of tricuspid valve dis-
ease is anticipated later this year.
Compassionate use
The MitraClip (Abbott Vascular, Abbott Park, IL, USA)
is a single-size clip device (cobalt-chromium covered with
polypropylene) with grippers above the arms to capture the
leaflets making an Alfieri-like repair of the mitral valve. Re-
cently, it has been implanted via transjugular access in 3 pa-
tients with severe TR. Using edge-to-edge repair in between
all three tricuspid commissures resulted in improvement in
the TR and HF symptoms [26]. Furthermore, successful
transfemoral implantations have been reported [27, 28].
The Trialign Percutaneous Annuloplasty System
(Mitralign Inc., Tewksbury, MA, USA) has been used
successfully in the treatment of functional TR [29, 30]. In
a transjugular venous approach, a pair of pledgeted sutures
are placed through the tricuspid annulus via a pledget de-
livery catheter. A dedicated plication lock device is used to
plicate the annulus, effectively bicuspidising the tricuspid
valve. The enrolment of 15 patients for a prospective, mul-
ticentre, FDA-approved, early feasibility assessment study
has been recently completed. The study aims to assess
the early safety and performance of a tricuspid-dedicated
Mitralign system in the SCOUT trial (Early Feasibility of
the Mitralign Percutaneous Tricuspid Valve Annuloplasty
System. NCT02574650). Possible advantages of the device
are the following: it has a small footprint with only a mini-
mal implant left behind; implantation is irrespective of the
annular size and adjacent anatomic structures; a 2nd pair
of pledgets can be implanted to optimise the result; the
procedure can be repeated in the future; and future access
and treatment options of the tricuspid valve are possible.
Reduction of left atrial pressure
Approximately half of the patients with HF suffer from HF-
pEF [31]. However, despite the apparent normality of LV
ejection fraction, symptoms and outcomes are similar to
those with HFrEF [32], particularly during physical activ-
ity. Both entities are associated with an increase in LA pres-
sure indicating impaired LV diastolic reserve [33, 34] and
leading to pulmonary congestion [35]. The disproportionate
rise in LA pressure is considered to provoke symptoms and
contribute to an increased morbidity and mortality [36].
Percutaneous perforation, balloon dilation and stent
implantation of the interatrial septum are established tech-
niques to create or enlarge atrial communication [37, 38].
However, complications include excessive desaturation,
spontaneous fenestration closure, stent occlusion or mi-
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Table 3 Transcatheter options for left atrial pressure reduction
Device Status Mechanism Size Access Product design
IASD CE mark May 2016 [39] Permanent IAS
shunt
8 mm 16 F Nitinol frame
V-Wave
Shunt
Proof-of-principle cohort study [40] Permanent IAS
unidirectional
shunt
5 mm 14 F Nitinol frame encapsulated with
expanded polytetrafluoroethylene
and 3 porcine pericardial leaflets
AFR First-in-man [41] Permanent IAS
fenestration
6, 8 or
10 mm
10, 11 or
12 F
Nitinol double-disc wire mesh
AFR atrial flow reducer, CE Conformité Européene, IAS interatrial septum, IASD interatrial shunt device
gration, difficulties in adjusting shunt size to achieve the
desired haemodynamic effect and the inability to remove
or close the shunt [37]. Two dedicated transcatheter de-
vices to reduce LA pressure are currently under clinical
investigation (Tab. 3).
Interatrial shunt device
The InterAtrial Shunt Device (IASD) system (Corvia Medi-
cal Inc., Tewkesbury, MA, USA) consists of a nitinol device
(outer diameter 19 mm) inserted percutaneously in the in-
teratrial septum to produce a permanent 8 mm atrial septal
communication (Fig. 4). The design is based on predictive
haemodynamic modelling which evaluated the relationship
between shunt size and LA pressure reduction [39]. It is im-
planted after a standard transseptal puncture near the middle
of the fossa ovalis (oval depression). A delivery catheter is
advanced over the wire into the left atrium. Subsequently,
the left side of the IASD is deployed and the delivery sys-
tem is retracted to make contact with the LA side of the
septum. After confirming the position, the right side of the
device is deployed onto the right atrial (RA) septal side.
Results of a pilot study have been published [40, 41].
The safety and device performance was demonstrated in the
REDUCE LAP-HF study (REDUCe Elevated Left Atrial
Pressure in Patients with Heart Failure), in which the St.
Antonius Hospital participated [42]. IASD placement was
successful in 66 of 68 patients (97%). There were no major
adverse events and there was no need for cardiac surgical
intervention for device-related complications. Device pa-
tency was sustained. Patients had significantly fewer HF
symptoms and were able to exercise longer, resulting in
a substantially better quality of life. Currently, the follow-up
REDUCE LAP-HF trial (NCT01913613) and a randomised
REDUCE LAP-HF I trial [43] are ongoing.
V-Wave shunt
The V-Wave shunt device (V-Wave Ltd, [previously Akiva],
Israel) is a percutaneously implanted device that creates
a unidirectional shunt from the left to the right atrium.
It is a self-expanding nitinol structure encapsulated with
expanded polytetrafluoroethylene. The exit funnel contains
three glutaraldehyde-fixed, porcine pericardial leaflets that
remain in the open position and are expected to close when
RA pressure exceeds LA pressure by 1–2 mmHg, prevent-
ing reverse right-to-left shunting.
A transseptal introducer sheath is advanced into the left
atrium after puncturing the fossa ovalis. The device is at-
tached with a three latches mechanism to a delivery cable,
loaded into the catheter. After opening the left side in the
left atrium, the system is pulled back into the interatrial
septum, where the device is detached and released.
Initial safety and beneficial outcomes were reported in
a single-centre proof-of-principle cohort study of 10 HFrEF
patients with successful implantation [44]. At 1 month,
all shunts were patent, with no thrombosis or migration.
After 3 months, NYHA functional class, quality of live
and 6-minute walk distance were significantly improved. To
evaluate the V-Wave device in both HFpEF and HFrEF pa-
tients, the RELIEVE-HF trial (REducing Lung Congestion
Symptoms Using thE V-wavE Shunt in Advanced Heart
Failure; NCT02511912) is planned. This is an observational
study with 1-year follow-up and estimated enrolment of
60 patients.
Atrial flow regulator
The Atrial Flow Regulator (Mia Medical, Istanbul, Turkey)
is a self-expandable double-disc wire mesh device con-
structed from 0.004–0.0075 inch nitinol braided into two
flat discs connected by a waist of 1–2 mm and central fen-
estration. The device is available in 6, 8 and 10 mm fen-
estration diameters with a total device diameter of 18, 24
and 30 mm. The first-in-man procedure was presented in
a patient with severe irreversible pulmonary arterial hyper-
tension [45]. Besides its use in pulmonary arterial hyperten-
sion patients (right-to-left shunt), its application may well
be extended to other HF populations to permit left heart
decompression.
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Fig. 4 Interatrial shunt de-
vice. InterAtrial Shunt Device
(IASD) system (Corvia Medical,
Tewkesbury, MA, USA) (left)
and an illustration of the final
position of the device in the in-
teratrial septum (right). The flow
goes from the left to the right
atrium. (Images adapted with
permission from Corvia Medi-
cal, Tewkesbury, MA, USA)
Neuromodulators
Increased sympathetic activation and reduced parasympa-
thetic tone, as reflected by reduced carotid baroreceptor
reflex sensitivity and/or decreased heart rate variability, are
potentially important contributors to HF progression asso-
ciated with poor outcome. Experimentally increasing the
parasympathetic tone by vagal nerve stimulation to nor-
malise the autonomic imbalance has recently emerged as
a potential therapy for HF. Several devices for vagal nerve
stimulation are being developed and studied in patients with
HF (Tab. 4).
CardioFit
The CardioFit (Biocontrol Medical Ltd., Yehud, Israel)
is an implantable neurostimulator system that can deliver
low current adjustable electrical pulses to stimulate the
vagal nerve. Parameters can be remotely programmed us-
ing a wireless system. The stimulator senses the heart rate
via an intracardiac electrode and delivers stimulation at
a fixed delay from the R wave. Upon implantation, the
intracardiac sensing electrode is positioned at the right
ventricular apex using a subclavian puncture. A cuff elec-
trode is implanted on the cervical vagus below the carotid
artery bifurcation and a stimulation lead is tunnelled under
the skin to join the sensing electrode and the stimulator. An
open-label study with 32 HF patients showed that chronic
vagal nerve stimulation may be safe and tolerable and
may improve quality of life and LV function at 1 year
[46]. More recently, the randomised NECTAR-HF (NEu-
ral Cardiac TheARpy for HF) trial failed to demonstrate
a significant effect on cardiac remodelling and functional
capacity, but improved quality of life [47].
Rheos system
The Rheos device (CVRx Inc., Minneapolis, MN, USA)
is a carotid baroreceptor reflex stimulator intended for the
treatment of resistant hypertension and HF. The non-ran-
domised feasibility DEBuT-HT (Device Based Therapy in
Hypertension) trial showed a sustained reduction of blood
pressure in 17 resistant hypertensive subjects and improved
functional capacity [48]. A sub-study showed a significant
decrease of LV mass index and an increase in LV ejection
fraction (65% to 67%) [49]. This may provide an attrac-
tive strategy for the treatment of HFpEF. The ongoing trial
Rheos HOPE4HF (Health Outcomes Prospective Evalua-
tion for Heart Failure With Ejection Fraction (EF) ≥40%,
NCT01720160) will provide information in this group of
patients.
HASS system
The Harmony Aortic Stimulation System (Enopace Biomed-
ical Ltd., Caesarea, Israel) is a minimally invasive im-
plantable neurostimulator system capable of delivering
stimulation to the aortic wall. An increase in pressure
suppresses the sympathetic tone of the heart and vascula-
ture and increases the parasympathetic tone of the heart.
Impulses from the Harmony system are sent to the brain
through neural pathways and result in a reduced arterial
stiffness and a reduced heart rate leading to a lowered
myocardial oxygen consumption and LV afterload. The
stimulation parameters can be remotely programmed using
a dedicated wireless communication system. Currently, the
ENDO-HF (Endovascular NeuromoDulation Treatment fOr
Heart Failure Patients; NCT02633644) feasibility Study,
in which the St. Antonius Hospital will be participating,
is recruiting to evaluate the safety and performance of the
HASS device in the treatment of 20 HF subjects during
a 5-year follow-up.
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Table 4 Transcatheter options for vagus nerve stimulation
Device Indication Status Method Location electrode
CardioFit HFrEF CE mark January 2009 [46] Bidirectional (efferent/
afferent) VNS
Cervical vagus approx. 3 cm
below the carotid artery bifur-
cation and RV apex
Rheos Persistent hyperten-
sion, HFpEF
CE mark October 2007 [47] Afferent VNS Carotid sinus
HASS HFpEF + HFrEF First-in-man Afferent VNS Thoracic aorta
CE Conformité Européene, HFpEF heart failure with preserved ejection fraction, HFrEF heart failure with reduced ejection fraction, RV right
ventricle, VNS vagal nerve stimulation
Future
Newer transcatheter structural heart interventions for
chronic HF are often based on surgical techniques. Some of
these surgical techniques have been abandoned due to a low
procedural success rate or unpredictable results. For exam-
ple, surgical LV remodelling, such as the Batista procedure,
in patients with a dilated cardiomyopathy was inferred not
a predictable reliable alternative to transplantation [50].
Consequently, device success of the newer transcatheter
devices should be carefully monitored. However, these
devices could be used in patients who are not eligible for
surgery due to their high operative risk. We learned from
the transcatheter aortic valve implantation experience that
this population might well benefit from transcatheter inter-
vention with regard to the survival rate and quality of life.
Furthermore, some of these devices might be considered as
a bridge to heart transplantation rather than definite treat-
ment, or could simply be used to improve quality of life.
However, we must realise that some of these devices might
even disqualify a patient for future left ventricular assist
device therapy or at least complicate the implantation.
Conclusions
Several new transcatheter structural heart interventions
for chronic HF, aiming at a variety of pathophysiologic
approaches, are currently being developed. Preliminary
results associated with most of these new interventions are
promising, with significant improvements in symptoms,
functional status, quality of life and haemodynamic perfor-
mance. However, the devices covered in this review are in
relatively early stages of development and it is too early to
compare devices within the same group based on clinical
results. Data from most of these technologies are therefore
restricted to first-in-man cases and observational studies,
limited by experience and number of patients. We need
larger randomised studies that can provide definite data on
the efficacy of these devices.
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link to the Creative Commons license, and indicate if changes were
made.
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